Drug Discovery Today

APRIL 24, 2023

(MIAMI) Researchers at the John P. Hussman Institute for Human Genomics at the University of Miami Miller School of Medicine have found that variations in chromatin accessibility, and thus gene expression, may explain why people of European descent with APOE4 gene variants have a greater risk of developing Alzheimer’s disease than people of African descent with similar genetics.

Disease 201

Disease Research 201

Drug Hunter

APRIL 23, 2023

There were plenty of scientific highlights from the literature that we didn’t have space for in Molecules of the Month – here’s a reader’s digest rounding up ~20 molecules of potential interest that we didn’t have space to highlight, including Pfizer’s covalent heterobifunctional BTK degrader, BMS’ brain-penetrant GSK-3β inhibitor, the discovery story of futibatinib from Taiho, and more snippets to jumpstart your reading!

Targeted Protein Degradation 130

Targeted Protein Degradation Drugs Trials 130

Chemical Biology and Drug Design

APRIL 28, 2023

Geraniol (GE) by its antioxidant, anti-inflammatory, and anti-apoptotic properties ameliorated global ischemia-reperfusion induced cascade of events such as oxidative stress, apoptosis, and inflammation. Thus, improved functional outcomes, and prevented neuronal infarction in rats. Abstract Geraniol (GE), an acyclic monoterpene, is a chief constituent of essential oils of herbs and fruits.

Treatment 100

Treatment Research 100

ASPET

APRIL 27, 2023

In situ clinical measurement of receptor occupancy (RO) is challenging, particularly for solid tumors, necessitating the use of mathematical models that predict tumor receptor occupancy to guide dose decisions. A potency metric, average free tissue target to initial target ratio (AFTIR), was previously described based on a mechanistic compartmental model, and is informative for near-saturating dose regimens.

Drugs 100

Drugs Pharmaceuticals 100

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Treatment

Drug Discovery Today

APRIL 27, 2023

3DSecret funded by European Innovation Council’s Pathfinder Open 2022, established under the EU Horizon Europe program.

113

113

FDA Law Blog: Biosimilars

APRIL 25, 2023

By Philip Won & Jeffrey K. Shapiro — Does your firm manufacture a “cyber device”? A recent amendment to the Federal Food, Drug, and Cosmetic Act (FD&C Act) added a new section about cybersecurity for “cyber devices.” If a device uses software that connects to the internet, it is most likely a cyber device and subject to new section 524B of the FD&C Act, “Ensuring Cybersecurity of Devices.

FDA 104

FDA Regulations Production Drugs 104

ProRelix Research

APRIL 27, 2023

Pharmacovigilance is defined by the World Health Organization (WHO) as “the science and activities relating to the detection, assessment, understanding, and prevention of adverse events or any other drug-related problems.” […] The post Pharmacovigilance Services for Signal Management: Process as per US FDA appeared first on ProRelix Research.

FDA 98

FDA Science Research Drugs 98

Drug Discovery Today

APRIL 28, 2023

New diagnostic test stratifies the likelihood of immunotherapy benefit across solid tumors

113

113

Antidote

APRIL 26, 2023

For individuals and companies that write health-focused blogs, continually finding topics to cover can be a challenge at times. Whether you’re a health influencer, patient advocacy organization, or another player in the clinical trial industry, finding unique topics to differentiate a blog is not always easy. However, through the below ideas and a unique voice, it is possible to write a plethora of clinical trial blogs that stick out from the rest.

Clinical Trials 98

Clinical Trials Trials 98

Chemical Biology and Drug Design

APRIL 27, 2023

Explainable artificial intelligence transparently influences the pre-drug development process with SHAP and LIME annotation methods. Abstract Recently, artificial intelligence (AI) techniques have been increasingly used to overcome the challenges in drug discovery. Although traditional AI techniques generally have high accuracy rates, there may be difficulties in explaining the decision process and patterns.

Drugs 100

Drugs Drug Development 100

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Drug Target Review

APRIL 26, 2023

Scientists from the Massachusetts Institute of Technology (MIT) and the University of Massachusetts Medical School (UMass), US, have collaborated to create a novel type of nanoparticle that can deliver messenger RNA that encodes for beneficial proteins to the lungs. Gene-editing methods allow researchers to modify DNA, resulting in alterations in physical characteristics such as eye colour and susceptibility to diseases.

RNA 98

RNA Medical Schools Engineering DNA 98

Eye on FDA

APRIL 28, 2023

In today’s Federal Register , the agency has announced that the Office of Prescription Drug Promotion (OPDP) is adding a new study effort to its research portfolio. The category of that body of research that is currently underway includes a range of topics, including an assessment of terms and phrases commonly used in prescription drug promotion, studying the comprehension and understanding of multiple indications used in consumer television advertisements, and endorser status and explicit

FDA 96

FDA Research Production Drugs 96

Antidote

APRIL 24, 2023

Eosinophilic esophagitis, also known as EoE, is a rare condition estimated to affect just one in 2,000 individuals. It is a disorder that impacts the esophagus (the tube connecting the mouth to the stomach) and leads to swallowing difficulties in both children and adults. To learn more about the impact of eosinophilic esophagitis , check out the information below.

94

94

Chemical Biology and Drug Design

APRIL 27, 2023

Synergistic combinations of inhibitors are sought after. A small helically-constrained peptide potently inhibited p53-HDM2 interaction and exerted anti-proliferative effects on p53 +/+ cells. A combination of this peptide and a USP7 inhibitor showed synergistic anti-proliferative effects. Synergistic inhibition of two important drug targets may lead to novel therapeutic strategies.

Regulations 100

Regulations Drugs Research 100

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

Drug Channels

APRIL 28, 2023

Today’s guest post comes from Megan Marchal, Director of Specialty Strategy at CoverMyMeds. Megan shares the story of Don, a cancer patient who struggled to access and afford his medications. She describes how human care plus an innovative, technology-driven patient support solution can help patients start therapy and get on the road to recovery. To learn more about CoverMyMeds’ specialty therapy solutions , visit Booth 1519 at Asembia's Specialty Pharmacy Summit in Las Vegas, April 30-May 4

Specialty Pharmacies 78

Specialty Pharmacies Pharmacy Therapies Drugs 78

Drug Patent Watch

APRIL 28, 2023

This chart shows the pharmaceutical companies with the most spray dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most spray dosed drugs… The post Which pharmaceutical companies have the most spray dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 78

Pharmaceutical Companies Pharmaceuticals Drugs 78

NIOSH Science Blog: Drugs

APRIL 28, 2023

Each year, NIOSH pauses on April 28th, Workers’ Memorial Day, to honor those who were killed or injured on the job. While tremendous progress has been made since Congress enacted the Occupational Safety and Health Act on this day in 1970, much still needs to be done. The Bureau of Labor Statistics reports that in 2021 more than 5,100 workers were killed and 2.6 million more were injured on the job.

64

64

Chemical Biology and Drug Design

APRIL 26, 2023

The binding of autoantibodies to aberrantly glycosylated regions of IgA immunoglobulins is the culprit of IgA nephropathy (IgAN). Glycopeptides mimicking the natural gd-IgA1 epitope were synthesized using optimized protocols and shown to capture anti-gd-IgA1 autoantibodies when coupled to poly-L-lysine polymers, thereby providing a potential strategy for antibody sequestration in IgAN.

Therapies 100

Therapies Disease Treatment Research 100

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

Drug Channels

APRIL 25, 2023

Baseball season is here! While we wait for the Phillies turnaround, let’s oil up our gloves, lace up our cleats, and run the bases around this month's biggest hits: Foul ball : OptumRx prefers higher prices for the first Humira biosimilar Strikeout : Copay accumulators hurt health equity Bench warmer : Surprise? Amazon has still not disrupted healthcare Spitting mad : Shady alternative funding programs (AFPs) face more scrutiny Plus, I sit down with Mark Cuban—and take a selfie.

Biosimilars 67

Biosimilars Drugs Pharmacy 67

Drug Patent Watch

APRIL 23, 2023

This chart shows the pharmaceutical companies with the most patents in Ukraine. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Ukraine? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 77

Pharmaceutical Companies Pharmaceuticals Drugs 77

NIOSH Science Blog: Drugs

APRIL 24, 2023

Overview Construction workers are at risk for injuries from many sources, but falls continue to be the leading cause of death (accounting for 37% [379 out of the 1015 fatalities] of all construction fatalities in 2021). This year marks the 10th annual National Safety Stand-Down to prevent falls in construction, an event to raise awareness that falls among construction workers are preventable.

64

64

Chemical Biology and Drug Design

APRIL 24, 2023

Raltegravir, an integrase inhibitor approved for the treatment of HIV infection, led to an increase in DNA damage and apoptosis in multiple myeloma that remains as an incurable malignancy. Abstract Raltegravir, the first integrase inhibitor approved for the treatment of HIV infection, has been implicated as a promising potential in cancer treatment.

DNA 100

DNA Treatment Research 100

addgene Blog

APRIL 27, 2023

We often think about the brain’s function in terms of its regions. But equally important is the way the brain connects across these regions, a process driven by neurons. By studying how neurons are physically connected, we can begin to understand how the brain works. It’s kind of like “the head bone’s connected to the neck bone,” but with about a hundred billion neurons and six hundred trillion connections (synapses.

59

59

Drug Patent Watch

APRIL 22, 2023

This chart shows the pharmaceutical companies with the most syrup dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most syrup dosed drugs… The post Which pharmaceutical companies have the most syrup dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 76

Pharmaceutical Companies Pharmaceuticals Drugs 76

NIOSH Science Blog: Drugs

APRIL 27, 2023

Exemplary science is the foundation for all National Institute for Occupational Safety and Health (NIOSH) research and prevention activities. Each year, NIOSH recognizes outstanding science and service from our employees. This year’s Science and Service Awards took place on April 27, 2023. The awards booklet contains the finalists, awardees, and honorable mentions as well as information on the occupational safety and health pioneers whom many of the awards are named after.

Science 56

Science Research 56

Chemical Biology and Drug Design

APRIL 24, 2023

Design, synthesis and molecular docking studies of novel quinoxaline derivatives as anticancer agent. Abstract As lung cancer was placed foremost part among other types of cancer in terms of mortality. Recent researches are widely focused on developing multi-targeted and site-specific targeted drug designs. In the present study, we designed and developed a series of quinoxaline pharmacophore derivatives as active EGFR inhibitors for the treatment of non-small cell lung cancer.

Treatment 100

Treatment Research Drugs 100

Covalent Modifiers

APRIL 28, 2023

Ming Fang, Gangam Srikanth Kumar, Stefano Racioppi, Heyang Zhang, Johnathan D. Rabb, Eva Zurek, and Qing Lin Journal of the American Chemical Society 2023 DOI: 10.1021/jacs.2c12325 Here we report the design and synthesis of a new class of bioorthogonal reagents called hydrazonyl sultones (HS) that serve as stable tautomers of highly reactive nitrile imines (NI).

52

52

Drug Patent Watch

APRIL 28, 2023

Annual Drug Patent Expirations for VUITY Vuity is a drug marketed by Abbvie Inc and is included in one NDA. It is available from one supplier. There are two patents… The post New patent for Abbvie Inc drug VUITY appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Target Review

APRIL 28, 2023

The heart is essentially a pump made of muscle, which is controlled by electrical signals. When these signals can become disrupted for several reasons, it can lead to a number of potentially dangerous heart conditions, such as cardiac arrest. Traditionally, a pacemaker can solve a disrupted heartbeat. It consists of a pulse generator, which emits electrical impulses through the wires to your heart.

Engineering 52

Engineering Research Therapies 52

Chemical Biology and Drug Design

APRIL 23, 2023

Our research unveiled new insights into SSA as a valuable candidate therapeutic agent for weakening glycolysis, and protruded the Akt/STAT3 pathway as a latent molecular target for SSA and glycolysis modulation. Abstract Saikosaponin A (SSA) has been revealed to have anti-breast cancer (BC) effect. However, the association between SSA and BC glycolysis is obscure.

Research 100

Research Production 100

Covalent Modifiers

APRIL 28, 2023

Lisa M. Boatner , Maria F. Palafox, Devin K. Schwepp, Keriann M. Backus Cell Chem. Bio. 2023 [link] Cysteine chemoproteomics provides proteome-wide portraits of the ligandability or potential “druggability” for thousands of cysteine residues. Consequently, these studies are facilitating resources for closing the druggability gap, namely, achieving pharmacological manipulation of ∼96% of the human proteome that remains untargeted by U.S.

Small Molecule 52

Small Molecule FDA Approval FDA Disease 52

Drug Patent Watch

APRIL 28, 2023

Annual Drug Patent Expirations for VAZALORE Vazalore is a drug marketed by Plx Pharma and is included in one NDA. It is available from one supplier. There are four patents… The post New patent for Plx Pharma drug VAZALORE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Crown Bioscience

APRIL 28, 2023

Patient-derived 3D ex vivo platforms are playing an increasingly important role in drug discovery. These translational platforms are high-throughput and highly clinically relevant because they accurately recapitulate the heterogeneity and molecular/genetic complexity observed in human tumors, including intact endogenous immune cell populations, fibroblasts, and other stromal components.

Drugs 52

Drugs 52